While the ability of OTS167 to inhibit FLT3 kinase activity and signaling was shared with other TKIs, only OTS167 is capable of downregulating FLT3 expression, circumventing resistance mechanisms including increased FLT3 or FLT3L expression and signaling in AML, or increased WT FLT3 expression in other hematologic malignancies such as MLL(KMT2A)-rearranged acute leukemias48. Here, KMT2A is linked to acute myeloid leukemia.